Nasdaq

ProMIS Neurosciences CEO Highlights Progress and Future Plans for Alzheimer's Treatment in Shareholder Letter

ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
Seeking Alpha

PMN ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...
TipRanks on MSN

ProMIS Neurosciences regains Nasdaq compliance

ProMIS Neurosciences ( ($PMN) ) has provided an announcement. On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance ...
Yahoo Finance

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
Yahoo Finance

ProMIS Neurosciences Announces Reverse Stock Split

Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...
Nasdaq

ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...
MarketWatch

ProMIS Neurosciences Shares Surge After FDA Fast-Track Designation for Alzheimer's Treatment

ProMIS Neurosciences shares surged after the company said the Food and Drug Administration granted a fast-track designation to the company's in-development treatment for Alzheimer's disease. Shares ...
Seeking Alpha

ProMIS Neurosciences announces positive pre-clinical data from Alzheimer’s treatment

ProMIS Neurosciences (NASDAQ:PMN) announced in vitro preclinical data that showed differentiation of PMN310 from other amyloid-beta-directed antibodies at the International Conference on Alzheimer’s ...
The Caledonian-Record

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ...

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease ...
Nature

The promise of PROMIS — is it ready for prime time in SLE?

Patient-reported outcomes are important predictors of morbidity and mortality. The validity and reliability of the Patient Reported Outcomes Measurement Information System (PROMIS) computerized ...
JSTOR Daily

Multidimensionality of the PROMIS self-efficacy measure for managing chronic conditions

Purpose This study investigated the PROMIS Self-Efficacy Measure for Managing Chronic Conditions (PROMIS-SE) domain distributions and examined the factor structure of the PROMIS-SE. Methods A total of ...